Servicio de Medicina Interna, Hospital Universitario Río Hortega, University of Valladolid, 47012 Valladolid, Spain.
Department of Cell Biology, Histology and Pharmacology, Faculty of Medicine, University of Valladolid, 47003 Valladolid, Spain.
Nutrients. 2022 May 5;14(9):1943. doi: 10.3390/nu14091943.
Calcifediol (25-OH-vitamin D3) is the prohormone of the vitamin D endocrine system. It is used to prevent and treat vitamin D deficiency. Calcifediol, as well as cholecalciferol (vitamin D3), is efficient and safe in the general population, although calcifediol has certain advantages over cholecalciferol, such as its rapid onset of action and greater potency. This review analyzed studies comparing the efficacy and safety of both calcifediol and cholecalciferol drugs in the short and long term (>6 months). Calcifediol was found to be more efficacious, with no increase in toxicity. We also assessed the predictability of both molecules. A 25OHD increase depends on the dose and frequency of calcifediol administration. In contrast, after cholecalciferol administration, 25OHD increase depends on more factors than dose and frequency of administration, also phenotypic aspects (such as obesity and malabsorption), and genotypic factors impacts in this increase.
钙化二醇(25-羟维生素 D3)是维生素 D 内分泌系统的前体激素。它用于预防和治疗维生素 D 缺乏症。钙化二醇和胆钙化醇(维生素 D3)在普通人群中均有效且安全,尽管钙化二醇相对于胆钙化醇具有某些优势,如起效迅速、效力更强。本综述分析了比较短期和长期(>6 个月)两种钙化二醇和胆钙化醇药物疗效和安全性的研究。研究发现,钙化二醇更有效,且没有增加毒性。我们还评估了这两种分子的可预测性。25OHD 的增加取决于钙化二醇的剂量和给药频率。相比之下,在给予胆钙化醇后,25OHD 的增加取决于比剂量和给药频率更多的因素,还取决于表型方面(如肥胖和吸收不良)和基因型因素对这种增加的影响。